Henry Schein, Inc. (HSIC)
適正価値ファンダメンタル
58
株価
$84.82
時価総額
$9.57B
パート1 · 企業の価値
概要
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users
Cited by Henry Schein as one of two national competitors in medical distribution, McKesson supplies the same office-based physicians and alternate-care sites with pharmaceuticals and medical-surgical products.
Its Medical segment distributes surgical and examination supplies to physician offices, ambulatory surgery centers and home-care providers, the same alternate-care customers Henry Schein Medical serves.
Named in Henry Schein's 10-K as its main U.S. rival, Patterson Dental sells the same consumables, equipment and practice-management software to the same dental offices, and has been privately held since Patient Square Capital took it off Nasdaq in April 2025.
The third full-service dental distributor in the United States, family-owned and unlisted, competing with Henry Schein practice by practice for the same dental supply and equipment budgets.
The other national medical competitor named in the 10-K, privately held, selling medical-surgical supplies to the same physician practices, surgery centers and long-term care facilities.
貸借対照表と流動性
売上高
$13.60B
直近12か月(2026/6/27まで)
純利益
$403M
直近12か月(2026/6/27まで)
フリーキャッシュフロー
$573M
自己資本合計
$3.25B
負債合計
$6.42B
流動比率
1.32
利払い倍率
4.28
負債/EBITDA
3.96
一株当たり利益(EPS)
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$77.47
現在株価
$84.82
安全マージン
-9.5%
適正価値レンジ
$53.98 - $100.95
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
24.76
ROE
12.3%
P/B レシオ
3.00
P/FCF
16.63
粗利益率
31.3%
ROIC
6.8%
収益性レーダー
価値創造(経済的モート)
ROIC
6.8%
WACC
7.5%
ROIC − WACC
-0.7 pp
ROICはおおむね資本コストと同水準です。企業はかろうじて資本コストを賄えている状態です。
ファンダメンタル分析基準
合格(18)
- EPS shows upward trend
- ROIC 6.8%
- Gross Margin 31.3%
- P/FCF 16.63
- P/B Ratio 3.00
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 12.4%
- Revenue Growth 5Y 5.4%
- Analyst Consensus 60% Buy
- Earnings Surprise avg 3.5%
- Earnings Quality (OCF/NI) 1.74
- Share Dilution -4.8%
不合格(9)
- EPS CAGR 1.29%
- Price CAGR 3.64%
- Operating Margin 5.0%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Fairly valued)
- PEG Ratio 7.91
- Net Margin Trend 3.0% vs 3.0%
- Piotroski F-Score 4/9
データなし(1)
- Dividend Payout NaN%
Piotroski F-スコア
まちまちのシグナル:一部の領域に注意が必要
利益の質
高品質:利益はキャッシュに裏付けられている
株式希薄化
株式を買い戻している。株主に友好的
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Ronald N. South | Senior VP & CFO | 63 |
| Mr. Michael Saul Ettinger | Executive VP & COO | 64 |
| Mr. Mark E. Mlotek | Executive VP & Chief Strategic Officer | 69 |
| Mr. Andrea Albertini | Chief Executive Officer of Global Distribution & Technology | 55 |
| Mr. Frederick M. Lowery | CEO & Director | 54 |
| Ms. Olga Timoshkina | VP of Corporate Finance & Chief Accounting Officer | - |
| Mr. Christopher Pendergast | Senior VP & CTO | 62 |
| Mr. Graham Stanley | VP of Investor Relations & Strategic Finance Project Officer | - |
| Ms. Kelly Murphy J.D. | Senior VP & General Counsel | 44 |
| Ms. Christine Sheehy | Senior VP & Chief Human Resources Officer | 57 |
監査リスク
4
取締役会リスク
8
報酬リスク
6
株主権利リスク
4
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容:テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for HSIC, sourced from Markets Gazette.
- 6/11/2026POSITIVEThis Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Henry Schein Inc. (HSIC) has received a bullish upgrade from Wall Street analysts, signaling a potentially positive outlook for the company's stock. While specific details of the upgrade and the analysts' reasoning are not provided in this snippet, such a shift in sentiment typically suggests that analysts foresee improved financial performance, strategic advantages, or favorable market conditions for HSIC. Investors often view analyst upgrades as a catalyst for stock price appreciation, potentially leading to increased buying interest and upward price momentum.
- 2/24/2026NEUTRALHenry Schein (HSIC) Q4 2025 Earnings Transcript
Investors in Henry Schein Inc. (HSIC) are poised to analyze the Q4 2025 earnings transcript, released on February 24, 2026. This event is pivotal for understanding the financial performance of the company, a global leader in distributing healthcare products and services to medical and dental practices. The report's analysis will provide crucial details on revenues, earnings per share (EPS), operating margins, and future outlook, which are fundamental elements for assessing the company's health and potential growth trajectories. While specific data is not yet available for direct evaluation, the transcript's release marks a key moment for the market, allowing deeper insight into management's statements and responses to analyst questions, thereby shaping expectations for the upcoming fiscal period and its impact on share value.
via Markets Gazette